BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA

Loading news article.

BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA | WAPE

BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA

Article summary

Related companies

Comments —